BioCentury | Jan 8, 2019
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting inflammatory macrophages could help treat Type II diabetes-associated pain. In a mouse model of Type II diabetes, the macrophage-targeting immunotoxin Mac1-saporin decreased disease-induced mechanical allodynia compared with vehicle. Also...
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....
BioCentury | Apr 27, 2015
Clinical News

TC-6499: Development discontinued

...BioCentury, April 6). Targacept Inc . (NASDAQ:TRGT), Winston-Salem, N.C. Product: TC-6499 Business: Gastrointestinal Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4)...
BioCentury | Apr 6, 2015
Company News

Catalyst Biosciences, Targacept deal

Targacept and Catalyst will merge, with Catalyst shareholders owning about 65% of the combined company and Targacept shareholders owning the remaining portion. The resulting company expects to have $40 million at closing. Targacept will provide...
BioCentury | Oct 27, 2014
Clinical News

Chantix varenicline regulatory update

A joint meeting of FDA's Psychopharmacologic Drugs Advisory and Drug Safety and Risk Management Advisory committees voted to retain boxed warning statements on Pfizer's Chantix varenicline for smoking cessation and reassess the statements once an...
BioCentury | Oct 20, 2014
Company News

Targacept, AstraZeneca deal

AstraZeneca ended an amended 2005 neurology deal with Targacept, which will regain all rights to compounds the biotech granted to the pharma, including AZD1446 (TC-6683). AZ said it ended the deal because preclinical studies did...
BioCentury | Oct 13, 2014
Clinical News

18-methoxycoronaridine: Phase I started

...Inc. , San Carlos, Calif. Product: 18-methoxycoronaridine (18-MC) Business: Infectious Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4) Description: Oral nicotinic acetylcholine receptor alpha(3)beta(4)...
Items per page:
1 - 10 of 73